Quintain Estates & Development PLC
14 February 2000
QUINTAIN SELLS LONDON THEATRE PORTFOLIO FOR £18m
Quintain Estates and Development PLC, the property investment
group, today announces that it has entered into a put and call
option of the sale of the Crescent theatre and investment
portfolio to the Ambassador Theatre Group for £18m cash. The
options are exercisable on or before 4th April 2000. The sale
price is in excess of book cost and proceeds will be used to
repay borrowings.
The portfolio of seven theatres include the Donmar Warehouse,
the Albery and Wyndhams, the Comedy, the Pheonix and the
Piccadilly Theatres.
Quintain acquired the theatres following its take over of
Chesterfield Properties PLC in July 1999.
For further information, contact:
Nick Shattock, Director, Quintain Tel: 0171 495 8968
Baron Phillips, Bankside Consultants Tel: 0171 220 7477
Notes to editors:
The portfolio of sever theatres are:
Albery and Wyndhams Theatres, St Martins Lane
Comedy Theatre, Panton Street
Phoenix Theatre, Charing Cross Road
Piccadilly Theatre, Denman Street
Whitehall Theatre, Whitehall
Donmar Warehouse, Neals Yard
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.